(+/-)-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid L-lysine salt | 408513-68-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: (+/-)-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid L-lysine salt
• 英文别名: (-)2-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid L-lysine salt；(2S)-2,6-diaminohexanoic acid;2-ethoxy-3-[4-[2-(2-ethyl-6-oxo-4-phenylpyrimidin-1-yl)ethoxy]phenyl]propanoic acid
• CAS: 408513-68-8
• 化学式: C₆H₁₄N₂O₂*C₂₅H₂₈N₂O₅
• 分子量: 582.697
• InChiKey: BHNOABDGWRVNFJ-ZSCHJXSPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.11
• 重原子数：
  42
• 可旋转键数：
  16
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  178
• 氢给体数：
  4
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  (-)2-ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid 、 L-赖氨酸 以 异丙醇 为溶剂， 反应 15.0h， 以to yield the title compound (weights about 4.3 g, mp (DSC) 114.93° C.)的产率得到(+/-)-Ethoxy-3-[4-[2-[2-ethyl-6-oxo-4-phenyl-1,6-dihydropyrimidin-1-yl]ethoxy]phenyl]propanoic acid L-lysine salt
  参考文献：
  名称：

  Pharmaceutically acceptable salts of heterocyclic compounds

  摘要：

  本发明涉及一般式(I)的药用可接受盐、其衍生物、类似物、互变异构体、立体异构体、多晶形式、药用可接受溶剂和含有它们的药用可接受组合物。

  公开号：

  US20020169175A1

文献信息

• SALTS OF PYRIMIDINE DERIVATIVES FOR USE AGAINST CORONARY HEART DISEASE AND ATHEROSCLEROSE
  申请人：Dr. Reddy's Laboratories Ltd.

  公开号：EP1363913A2

  公开（公告）日：2003-11-26
• [EN] PHARMACEUTICALLY ACCEPTABLE SALTS OF HETEROCYCLIC COMPOUNDS<br/>[FR] SELS DE COMPOSES HETEROCYCLIQUES PHARMACEUTIQUEMENT ACCEPTABLES
  申请人：REDDY RESEARCH FOUNDATION

  公开号：WO2002062798A2

  公开（公告）日：2002-08-15

  The present invention relates to pharmaceutically acceptable salts of compound of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. The present invention relates to pharmaceutically acceptable salts of the general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs and pharmaceutically acceptable compositions containing them.